On September 19, 2025, Xencor, Inc. announced the appointment of Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies is a biochemist and cell biologist with over 25 years of experience in biotechnology and drug development.
Dr. Deshaies previously served as senior vice president of global research at Amgen Inc., where he oversaw all research activities, including the nomination of over 50 clinical candidates. He also expanded Amgen’s capabilities for discovering and optimizing multispecific drug candidates.
Xencor's President and Chief Executive Officer, Bassil Dahiyat, Ph.D., stated that Dr. Deshaies' deep understanding of biological mechanisms and track record of translating scientific insights into medicines will be valuable as Xencor advances its pipeline of XmAb drug candidates.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.